PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
4.68%
Positive revenue growth while 3088.T is negative. John Neff might see a notable competitive edge here.
7.34%
Gross profit growth above 1.5x 3088.T's 1.80%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
14.18%
EBIT growth similar to 3088.T's 13.34%. Walter Schloss might infer both firms share similar operational efficiencies.
14.18%
Operating income growth similar to 3088.T's 13.34%. Walter Schloss would assume both share comparable operational structures.
28.60%
Positive net income growth while 3088.T is negative. John Neff might see a big relative performance advantage.
28.61%
Positive EPS growth while 3088.T is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
28.61%
Positive diluted EPS growth while 3088.T is negative. John Neff might view this as a strong relative advantage in controlling dilution.
-0.00%
Share reduction while 3088.T is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.00%
Reduced diluted shares while 3088.T is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
28.80%
10Y revenue/share CAGR under 50% of 3088.T's 105.50%. Michael Burry would suspect a lasting competitive disadvantage.
48.70%
5Y revenue/share CAGR at 50-75% of 3088.T's 69.49%. Martin Whitman would worry about a lagging mid-term growth trajectory.
22.33%
3Y revenue/share CAGR under 50% of 3088.T's 57.31%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
63.58%
Net income/share CAGR at 50-75% of 3088.T's 96.99%. Martin Whitman might question if the firm’s product or cost base lags behind.
18.88%
5Y net income/share CAGR above 1.5x 3088.T's 11.33%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
12.08%
Positive short-term CAGR while 3088.T is negative. John Neff would see a clear advantage in near-term profit trajectory.
161.83%
10Y equity/share CAGR at 50-75% of 3088.T's 307.02%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
104.73%
5Y equity/share CAGR at 50-75% of 3088.T's 152.27%. Martin Whitman would question a shortfall in capital accumulation vs. the competitor.
50.85%
Below 50% of 3088.T's 121.88%. Michael Burry suspects a serious short-term disadvantage in building book value.
81.82%
10Y dividend/share CAGR at 50-75% of 3088.T's 133.33%. Martin Whitman suspects the firm lags in returning cash to shareholders over the decade.
77.78%
5Y dividend/share CAGR above 1.5x 3088.T's 40.00%. David Dodd checks if the firm's mid-term cash flows justify a faster dividend growth rate.
45.45%
3Y dividend/share CAGR of 45.45% while 3088.T is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
43.48%
AR growth well above 3088.T's 50.29%. Michael Burry fears inflated revenue or higher default risk in the near future.
3.24%
We show growth while 3088.T is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
5.71%
Asset growth above 1.5x 3088.T's 0.08%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
3.66%
Positive BV/share change while 3088.T is negative. John Neff sees a clear edge over a competitor losing equity.
111.10%
Debt growth far above 3088.T's 17.22%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-40.01%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.